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Abstract
Shift in the cellular homeostasis of the organic osmolyte taurine has been
associated with dysregulation of the volume-regulated anion channel (VRAC)
complex, which comprises leucine-rich repeat-containing family 8 members
(LRRC8A-E). Using SDS-PAGE, western blotting, qRT-PCR, and tracer tech-
nique ([3H]taurine) we demonstrate that reactive oxygen species (ROS) and
the cell growth-associated kinases Akt/mTOR, play a role in the regulation of
VRAC in human alveolar cancer (A549) cells. LRRC8A is indispensable for
VRAC activity and long-term exposure to hypoosmotic challenges and/or
ROS impairs VRAC activity, not through reduction in total LRRC8A expres-
sion or LRRC8A availability in the plasma membrane, but through oxidation/
inactivation of kinases/phosphatases that control VRAC activity once it has
been instigated. Pursuing Akt signaling via the serine/threonine kinase mTOR,
using mTORC1 inhibition (rapamycin) and mTORC2 obstruction (Rictor
knockdown), we demonstrate that interference with the PI3K-mTORC2-Akt
signaling-axes obstructs stress-induced taurine release. Furthermore, we show
that an increased LRRC8A expression, following exposure to cisplatin, ROS,
phosphatase/lipoxygenase inhibitors, and antagonist of CysLT1-receptors, cor-
relates an increased activation of the proapoptotic transcription factor p53. It
is suggested that an increase in LRRC8A protein expression could be taken as
an indicator for cell stress and limitation in VRAC activity.
Introduction
Volume-sensitive organic osmolyte release
Mammalian cells counteract volume changes, following
osmotic perturbation, by accumulating / releasing osmo-
lytes (Hoffmann et al. 2009; Lambert et al. 2015b). A
reduction in cell volume following osmotic cell swelling
(regulatory volume decrease, RVD) or as part of the apop-
totic cell death process (apoptotic volume decrease, AVD)
will in most mammalian cells imply net loss of inorganic
ions (K+, Cl) via volume-sensitive ion channels as well as
net loss of amino acids via a volume-sensitive leak pathway
for organic osmolytes (Lang 2007; Hoffmann et al. 2009).
Furthermore, cells have the ability to shift the cell volume
to instigate cell proliferation, migration, and apoptosis
(Lang 2007; Hoffmann et al. 2009). Today it is assumed
that volume-regulated anion channel (VRAC) complexes,
composed of members of the leucine-rich repeat-contain-
ing protein 8 family (LRRC8A-E) (Planells-Cases et al.
2015; Stauber 2015; Schober et al. 2017), are responsible
for the volume-sensitive chloride current (ICl, swell) as well
as swelling-induced release of neurotransmitters and
organic osmolytes (e.g., GABA, aspartate, glutamate, and
taurine) (Qiu et al. 2014; Voss et al. 2014; Mongin 2016;
Syeda et al. 2016; Lutter et al. 2017).
Each LRRC8 subunit consists of four transmembrane
helix domains with a cytosolic C-terminal containing up to
17 leucine-rich repeat-domains. Co-immunoprecipitation
in HEK cells shows that LRRC8A interacts with other
LRRC8 subunits, forming a heteromeric, channel complex
(Voss et al. 2014; Planells-Cases et al. 2015; Stauber 2015;
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Schober et al. 2017). LRRC8A has been shown to be indis-
pensable for VRAC activity (Qiu et al. 2014; Voss et al.
2014). Knockdown (KD) of the LRRC8D subunit disrupts
taurine, myo-inositol and GABA efflux during swelling-
induced RVD, albeit not to the same degree as KD of
LRRC8A (Planells-Cases et al. 2015; Lutter et al. 2017).
LRRC8D KD has apparently no effect on ICl, swell (Planells-
Cases et al. 2015; Lutter et al. 2017). Recently, Mongin and
coworkers demonstrated that LRRC8D KD in rat astrocytes
reduced the swelling-induced efflux of [3H]taurine by 50%,
abolished myo-[3H]inositol efflux but had no effect on D-
[14C]aspartate efflux (Schober et al. 2017). It was also
demonstrated that the effect of LRRC8D KD on taurine
release was lifted when extracellular pH was shifted from a
physiological pH 7.4 ( 4% taurine negatively charged), to
pH 9.8 ( 91% taurine negatively charged) (Schober et al.
2017). This provides evidence that a LRRC8A/D containing
VRAC complex favors transports of the electroneutral,
organic osmolytes.
Attempts have been made to illustrate the correlation
between LRRC8A protein expression and VRAC activity.
Exposure to protolichesterinic acid, derived from lichens,
has previously been demonstrated to reduce LRRC8A
expression and concomitantly volume-sensitive taurine
release in human alveolar carcinoma (A549) cells
(Thorsteinsdottir et al. 2016). Furthermore, a reduced tau-
rine release following hypoosmotic perturbation from cis-
platin-sensitive A549 cells correlated with a reduced
expression of LRRC8A in the plasma membrane (Sørensen
et al. 2016b). However, overexpression of MYC- or GFP-
tagged LRRC8A plasmids, resulted in a decrease in ICl,Swell
in HEK293 and HeLa cells although the exogenous protein
via immunocytochemistry was shown to reach the plasma
membrane (Lee et al. 2007; Qiu et al. 2014). It appears
that posttranslational modulation of LRRC8 proteins or
modulators of the channel complex VRAC dictates activity.
Volume-sensitive taurine release – Reactive
oxygen species (ROS)
The cell signaling pathway, activated by osmotic cell swel-
ling and leading to release of taurine has been characterized
in various cell types. In the case of Ehrlich ascites tumor
cells and NIH3T3 mouse fibroblasts activation of volume-
sensitive taurine release involves phospholipase A2 (PLA2)
mediated mobilization of arachidonic acid (AA) from
phospholipids (the PLA2 subtype is cell type-specific), 5-
lipoxygenase (5-LO)-mediated oxidation of AA to leuko-
trienes, and subsequently a cysteine-leukotriene-receptor
(CysLT1)-dependent activation of the taurine release sys-
tem (Lambert et al. 2015b). In the A549 cell line it has like-
wise been demonstrated that 5-LO and CysLT1 are
essential components for taurine release during RVD
(Holm et al. 2013). Once activated, the volume-sensitive
taurine release can be boosted by exposure to ROS, and
through Ca2+ mobilization (Holm et al. 2013; Lambert
et al. 2015b). ROS are produced within minutes following
osmotic cell swelling (Lambert 2003; Ørtenblad et al. 2003;
Varela et al. 2004; Diaz-Elizondo et al. 2006; Friis et al.
2008; Holm et al. 2013) and it has been shown that the
NADPH-oxidase NOX4 contributes to swelling-induced
ROS production in NIH3T3 (Lambert 2003; Friis et al.
2008) and A549 (Holm et al. 2013) cells. Similarly, NOX4
and NOX2 have been demonstrated to be involved in swel-
ling-induced ROS production in hepatoma cells (Varela
et al. 2004) and rabbit atrial/ventricular myocytes (Deng
et al. 2010). An increased ROS accumulation, simulated by
addition of hydrogen peroxide (H2O2) or inhibition of
antioxidative enzymes (e.g., catalase), has accordingly been
shown to potentiate swelling-induced taurine release (Lam-
bert 2003, 2007; Lambert et al. 2014). The effect of ROS on
the volume-sensitive taurine release is mimicked by the tyr-
osine phosphatase inhibitor sodium orthovanadate, indi-
cating that ROS block tyrosine phosphatases presumably
through oxidation of cysteines in their catalytic center
(Meng et al. 2002). It is assumed that increased net tyro-
sine-phosphorylation of elements in the volume-sensitive
signaling cascade and/or members of the LRRC8 family,
boosts the transport efficiency of the VRAC complex (Lam-
bert et al. 2015b). In this context, it is noted that pro-
teomic studies reveals that LRRC8 proteins contains an
array of sites available for posttranslational modification
(phosphorylation, acetylation, ubiquitination, and N-
linked glycosylation) (Abascal and Zardoya 2012) and that
LRRC8A/LRRC8E heteromeric channels, when exoge-
nously expressed in Xenopus oocyte, are activated by oxida-
tion, whereas exogenously expressed LRRC8A/LRRC8C as
well as LRRC8A/LRRC8D channels are inhibited by oxida-
tion (Gradogna et al. 2017).
Volume-sensitive taurine release – Akt-
mTOR signaling
The serine/threonine kinases Akt (protein kinase B) and
mTOR have been demonstrated to modulate swelling-
induced taurine release (Lezama et al. 2005; Holm et al.
2013; Lambert et al. 2015b). In cultured cerebellar granule
neurons, cell swelling stimulates Akt, whereas inhibition of
kinases upstream to Akt (ErbB4, FAK, Src, and PI3K (Phos-
phatidylinositol-4,5-bisphosphate 3-kinase)) suppresses
Akt activation and reduces the concomitant release of tau-
rine (Lezama et al. 2005). Akt activation, which is often
associated with cell proliferation, growth, survival, metabo-
lism, and autophagy (Manning and Toker 2017), implies
recruitment of Akt to phosphatidylinsitol-3,4,5-tripho-
sphate (PIP3) in the inner leaflet of the plasma membrane
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and a subsequent sequential phosphorylation of Akt at
Thr-308 and Ser-473 (Hay 2005). Akt activity is indirectly
reversed by the tumor suppressor PTEN (phosphatase and
tensin homolog), a phosphatase that antagonizes PI3K
activity by dephosphorylation of PIP3. It is the phospho-
inositide-dependent kinase-1 (PDK1) that is responsible
for phosphorylation of Akt at Thr-308, whereas phosphory-
lation of Ser-473 on Akt requires activation of mammalian
target of rapamycin (mTOR). mTOR represent the catalytic
subunit of two distinct complexes; mTORC1 and
mTORC2, where mTORC1 operates down-stream to Akt
and mTORC2, which is typically activated by extracellular
stimuli such as growth factors and insulin in a PI3K-depen-
dent manner (Liu et al. 2015; Manning and Toker 2017),
activates Akt. mTORC2 is, in contrast to mTORC1, insen-
sitive to rapamycin inhibition (Bai et al. 2017). In this con-
text it has been suggested that PIP3, besides PDK1 and Akt,
also recruits SIN1 to the plasma membrane where SIN1,
through a conformational change in the mTORC2 com-
plex, relives auto-inhibition of mTOR and hence ensures
mTOR kinase activity (Manning and Toker 2017). We have
previously shown that mTORC1 activity is significantly
increased within minutes following osmotic cell swelling
but reduced following prolonged hypotonic treatment
(Lambert et al. 2014).
LRRC8A protein expression and p53-
mediated signaling to apoptosis
Apoptosis is a well-orchestrated cell death program, char-
acterized by chromatin condensation, membrane budding,
phosphatidylserine (PS) externalization to the outer leaflet
of the plasma membrane, cell shrinkage, and intracellular
protein degradation due to activation of caspases. Kinases,
triggered by reversible DNA damage, activate the check-
point kinase 2, which subsequently phosphorylates the
tumor suppressor p53 (Roos and Kaina 2013). p53
orchestrates expression of genes involved in DNA repair,
cell cycle arrest, and apoptosis (Hientz et al. 2017). In the
latter case, this includes proapoptotic members of the
Bcl-2 protein family, for example, PUMA (p53-upregu-
lated modulator of apoptosis) and BAX (Bcl-2-associated
X protein). PUMA and BAX facilitate mitochondrial cyto-
chrome-c release, activation of caspase-9 through interac-
tion with APAF-1 (apoptotic protease-activating factor),
and finally activation of executioner caspases (caspases 3,
6, and 7) (Dasari and Tchounwou 2014; Mehmood
2014). Phosphorylation and activation of p53 is known to
follow hyperosmotic cell shrinkage and exposure to Pt-
based chemotherapeutic drugs, for example, cisplatin
(Friis et al. 2005; Lambert et al. 2015a; Sørensen et al.
2016b) and the subsequent activation of apoptotis is
clearly dependent on LRRC8A expression/VRAC activity
(Hoffmann and Lambert 2014; Planells-Cases et al. 2015;
Sørensen et al. 2016a). Originally it was assumed that
resistance to cisplatin reflected limitation in osmolyte loss
due to impairment of the activity of volume-sensitive
osmolyte transporters (Poulsen et al. 2010). However,
more recently it has been demonstrated that cisplatin
resistance correlated with limitation in cisplatin uptake
and consequently annulation of the intracellular, cis-
platin-induced apoptotic cell death signaling (Planells-
Cases et al. 2015; Sørensen et al. 2016a). As cisplatin
uptake in cisplatin-sensitive A2780 cells is reduced by
pharmacological inhibition of VRAC and by LRRC8A KD
(Sørensen et al. 2016a) it is assumed that any stress-
induced modulation of LRRC8A expression/ VRAC activ-
ity will impact cisplatin sensitivity through limitation of
drug uptake and hence impairment of the instigation of
AVD and intracellular apoptotic cell signaling.
With emphasis on acute as well as long-term exposure to
ROS (H2O2), cisplatin and adaptation to hypotonic media
we have used the A549 cell line to investigate the correla-
tion between cell stress, total LRRC8A mRNA/protein
expression, LRRC8A protein expression in the plasma
membrane and VRAC activity. It will be demonstrated that
prolonged cell stress reduce VRAC activity – not through
reduction in total expression/plasma membrane availability
of the LRRC8A protein but more likely through shift in the
activity of kinases/phosphatases involved in volume-sensi-
tive cell signaling that ensures VRAC activity. It is suggested
that an increased LRRC8A protein expression indicates cell
stress as it correlates with activation of the proapoptotic
transcription factor p53, following exposure to cisplatin,
ROS, and pharmacological inhibitors of key elements,
involved in release of organic osmolytes (taurine).
Materials and Methods
Chemicals and antibodies
Antibiotics (penicillin, streptomycin), Roswell Park
Memorial Institute (RPMI-1640) and Dulbecco’s Modi-
fied Eagle (DMEM) media, fetal calf serum (FBS), and
trypsin/EDTA were from Invitrogen, Denmark. [1,2-3H
(N)]-taurine (NET1205250UC, specific activity: 0.707
TBq/mmol) and scintillation cocktail (Ultima GoldTM)
were from Perkin Elmer, Denmark. Unless otherwise
stated, chemicals were purchased from Sigma Aldrich (St.
Louis, MO) or Calbiochem (Europe). The following stock
solutions were prepared: ETH 615-139 (donated by Dr. I
Ahnfelt-Rønne, Løvens Kemiske Fabrik, Denmark,
2 mmol L1, EtOH); bpV(HOpic) (Bisperoxo(bipyridine)
oxovanadium, 200 lmol L1, ddH2O); MG132 (carboben
zoxy-Leu-Leu-leucinal, 10 mmol L1, DMSO); Vanadate
(Sodium orthovanadate, 20 mmol L1, ddH2O);
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Wortmannin (1 mmol L1, DMSO); Rapamycin
(400 lmol L1, EtOH); BHT (Butylated hydroxytoluene,
400 mmol L1, EtOH); Trypsin-EDTA solution (Invitro-
gen, 5 mg porcine trypsin, 2 mg EDTA pr. mL PBS); Zafir-
lukast (N-[3-[[2-Methoxy-4-[[[(2-methylphenyl) sulfonyl]
amino]carbonyl]phenyl]methyl]-1-methyl- 1H-indol-5-yl]
carbamic acid cyclopentyl ester, 30 mmol L1, DMSO).
Primary antibodies
Anti-b-actin (A1978, mouse monoclonal Ab, 42 kDa,
Sigma-Aldrich; 1:1000); Anti-Akt // Anti-Phospho-Akt
(9272 // 4058, rabbit Ab, 60 kDa, Cell Signaling, Danvers,
MA; 1:500 // 1:250 (P-Akt)); Anti-histone H3 (9717, rabbit
Ab, 18 kDa, Cell Signaling 1:250); Anti-human-LRRC8A
(SAB1412855, mouse monoclonal Ab, 95 kDa, Sigma-
Aldrich; 1:250); Anti-FoxO3a // Anti-Phospho-FoxO3
(Ser413) (2497//8174, rabbit Ab, 82-97 kDa, Cell Signaling;
1:250//1:250); Anti-GAPDH (ZG003, mouse monoclonal
Ab, 37 kDa, Thermo Fisher, 1:500); Anti-NOXA (14766,
rabbit Ab, 10 kDa, Cell Signaling; 1:100); Anti-human
p21Waf1/Cip1 (P1484, mouse monoclonal Ab, 21 kDa,
Sigma-Aldrich, 1:250); Anti-Phospho-p53 (9284, rabbit
Ab, 53 kDa, Cell Signaling, 1:500); Anti-Rictor (9476, Cell
Signaling, 200 kDa, 1:1000) and monoclonal Anti-Na+/K+-
ATPase (clone M7-PB-E9, Sigma-Aldrich, 110 kDa, 1:150).
Secondary antibodies
Stabilized peroxidase-conjugated goat anti-mouse (Ther-
mo Scientific 1:5000) and Goat Anti-Rabbit (Thermo Sci-
entific; 1:5000). All antibodies were prepared in NaAzid
free blocking buffer. Luminol and enhancer for western
blotting were from Thermo Scientific.
Inorganic solutions
Phosphate-buffered saline (PBS) contained 137 mmol L1
NaCl, 2.6 mmol L1 KCl, 6.5 mmol L1 Na2HPO4, and 1.5
mmol L1 KH2PO4. Isotonic NaCl solution (320 mOsM)
contained 152.5 mmol L1 NaCl, 5 mmol L1 KCl,
1 mmol L1 Na2HPO4, 1 mmol L
1 CaCl2, 1 mmol L
1
MgSO4, plus 10 mmol L
1 N-2-hydroxyethyl piperazine-
N’-2-ethanesulfonic acid (HEPES).HypotonicNaCl solution
was prepared by reducing the NaCl concentration without
changing the concentration of the other components. pHwas
in all solutions adjusted to7.4 andosmolaritiesmeasuredona
KnauerOsmometerAutomatic.
Cell cultures
Wild type, human lung adenocarcinomic alveolar epithe-
lial cells (A549WT), were purchased from American Type
Culture Collection (ATCC, Manassas, VA) and grown in
Greiner Bio-one tissue culture flasks (T75, 75 cm2 growth
area) in DMEM supplemented with 10% fetal bovine
serum (v/v) and penicillin / streptomycin (100 units peni-
cillin/100 lg streptomycin pr. ml). Cisplatin-resistant
A549 cells (A549RES) were developed by exposing
A549WT cells to an increasing concentration (up to
10 lmol L1) of cisplatin for a period of 6 months and
maintaining its resistant phenotype by treating the cells
with 10 lmol L1 cisplatin every second passage (see
(Sørensen et al. 2016b)). Wild-type human embryonic
kidney (HEK-293) cells and HEK-293 lrrc8A/ (clone
E7, gift from Prof. Thomas J. Jentsch FMP (Leibniz-Insti-
tut fuer Molekulare Pharmakologie) and MDC (Max-Del-
brueck-Centrum fuer Molekulare Medizin), D-13125
Berlin, Germany) were cultured in 75 cm2 culture flasks
(CellStar, Grenier Bio, Germany) in RPMI or DMEM
media, respectively. Hypotonic growth media were
obtained by dilution of the growth media with sterile
water. All cell cultures were subcultured two times a week
using 0.25% trypsine/EDTA in PBS and kept at 37°C, 5%
CO2, and 100% humidity.
Rictor knockdown
To eliminate mTORC2 activity transient knockdown of
Rictor was carried out using a pool of four siRNA con-
structs against Rictor mRNA (SMARTpool: ON-TAR-
GETplus, GE Healthcare, Dharmacon). MISSION
Universal Negative Control siRNA (Sigma Aldrich) was
used to create a baseline for knockdown efficiency.
Knockdown efficiency was estimated by western blot anal-
ysis of Rictor. Cells, grown to 50% confluence, were
transfected with Rictor siRNA or negative control (scram-
ble) siRNA at a concentration of 50 nmol/L using Lipo-
fectamine 2000 Transfection Reagent (Thermo Fisher
Scientific). After 4 h incubation, the medium was
replaced by transfection reagent-free medium, and cells
incubated for another 20 h before analysis.
SDS-PAGE and western blotting
SDS-PAGE and western blotting were used to quantify
changes in protein levels. Cells were grown to 80-90%
confluence in a 6 cm petri dish, washed in ice cold PBS
cells, and lysed in lysis buffer containing 1% Sodium
dodecyl sulfate (SDS), 150 mmol L1 NaCl, 20 mmol L1
HEPES, 1 mmol L1 EDTA, 0,5% Triton X-100, 1 mmol
L1 Na3VO4 and 1% protease inhibitor cocktail. The lysates
were sonicated before centrifugation (20,000 g, 5 min,
5°C) to precipitate insoluble cell material. The protein con-
tent in the supernatant was determined using a Bio-Rad
DC Protein Assay (Bio-Rad, Hercules, CA) and lysates
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subsequently diluted in ddH2O to 20–40 lg per loading.
Protein samples were mixed with NuPAGE sample buffer
containing dithiothreitol (DTT) and proceeded for SDS-
PAGE gel electrophoresis (NuPAGE precast 10% or 4–12%
Bis-tris gels in NuPAGE MOPS SDS running buffer, Invitro-
gen, Waltham, MA) in NOVEX chambers under reducing/
denaturing conditions. To indicate the molecular weight of
proteins we used a benchmark protein ladder (Invitrogen).
Following protein separation by electrophoresis, we used
NuPAGE transfer buffer (Invitrogen) for protein transfer to
nitrocellulose membranes (Frisinette, Denmark). Successful
protein transfer was verified by Ponceau S staining. Unspeci-
fic protein-binding to membranes was prevented by incuba-
tion of the membranes in TBST (0.01 mol/L Tris–HCl,
0.15 mol/L NaCl, 0.1% Tween 20, pH 7.4) containing 5%
nonfat dry milk at 37°C for 1 h. Membranes were incubated
with primary antibodies diluted in blocking buffer overnight
at 4°C before being washed in TBST and exposed to sec-
ondary antibodies for 1 h at room temperature. Membranes
were developed using BCIP/NBT (KPL, Gaithersburg, MD),
scanned and bands quantified using UN-SCAN-IT (Silk Sci-
entific).
Determination of rate constants for taurine
release and inactivation of the VRAC
complex
Swelling-induced taurine efflux was estimated at room
temperature in A549 and HEK cells grown to 80% con-
fluence in six-well polyethylene culture (cells) or Poly-
Lysine coated (Greiner Bio-One) plates, respectively, as
previously described (Sørensen et al. 2016b). Each well
represented one release experiment. Cells were loaded
with [3H]taurine (37000 Bq/well) in growth medium for
2 h (37°C, 5% CO2, 100% humidity). Taurine release
experiments were initiated by 3 times wash of the wells
with 1 mL isotonic NaCl medium to remove residual
extracellular isotope and growth media. Release of
[3H]taurine was subsequently followed with time by
transferring the NaCl medium from each well to individ-
ual scintillation vials (Snaptwist Scintillation vial, 6.5 mL,
VWR) and replacing it with fresh medium at 2-min
(A549 cells) or 5-min (HEK cells) intervals. The experi-
ment was run for the total of 30–40 min with the isotonic
medium being replaced by hypotonic media 10 min after
initiation of the efflux experiment. At the end of the
assay, remaining intracellular [3H]taurine was extracted
by addition of 1 mL 1 mol/L NaOH (1 h, shaking table)
followed by two times wash with 1 mL ddH2O. 3.5 mL
scintillation fluid was added to each vial and [3H]-activ-
ity detected by b-scintillation counting (Perkin Elmer
scintillation counter, Waltham, MA). Total [3H]activity
in the cell system was calculated as the sum of [3H]
activity released during the efflux experiment and in the
NaOH/water washouts. The fractional rate constant for
taurine release (k, min1) was calculated from the equa-
tion: k = [ln(X1)  ln(X2)]/(t1–t2) (X1 and X2 denote the
fraction remaining in the cell at time t1 and t2, respec-
tively) and plotted versus time. The rate constant for tau-
rine release under isotonic conditions was determined as
the mean of the 2–3 values obtained prior to the hypo-
tonic exposure. Maximal swelling-induced rate constant
was determined as the highest rate constant following
hypotonic exposure. Inactivation of the VRAC complex
activity at a given time point “t” following hypotonic
activation of its activity was determined as (kmax–kt)/
(kmax–kiso), where kmax, kiso are the maximal and the iso-
tonic rate constant and kt the constant at time “t”.
Quantitative real-time polymerase chain
reaction (qRT-PCR)
qRT-PCR was performed to quantify LRRC8A, LRRC8D,
and Actin-related protein 2/3 ARP2/3 (house-keeping
gene) mRNA accumulation as previously described (Søren-
sen et al. 2014). Nucleospin RNA II kit (MACHEREY
NAGEL, Germany) was used for RNA isolation from cells
grown to 90% confluence in 10 cm petri dishes. Reverse
transcription was performed by incubating 1 lg RNA
(NanoDrop; Thermo Fisher Scientific) with nucleotide
solution (dNTP mix) plus oligo dT primer at 65°C for
5 min and subsequently with strand buffer plus dithiothre-
itol (DTT) at 42°C for 2 min. Superscript II reverse tran-
scriptase was added and mixture incubated at 42°C for
50 min. The transcription reaction was stopped by raising
the temperature to 70°C for 15 min. mRNA accumulation
was determined with Brilliant II SYBR Green QPCR
master mix plus predesigned and validated KiCqS-
tart SYBR Green Primers (Sigma Aldrich), for example:
LRRC8A (Fwd: GGGTTGAACCATGATTCCGGTGAC//
Rev: GAAGACGGCAATCATCAGCATGAC; LRRC8D
(Fwd: ATGGAGGAGTGAAGTCTCCTGTCG//Rev: CTTC
CGCAAGGGTAAACATTCCTG); ARP (Fwd: CGACCTG
GAAGTCCAACTAC //Rev: ATCTGCTGCATCTGCTTG).
qRT-PCR was performed using the following conditions:
10 min at 95°C followed by 40 cycles (30 sec at 95°C,
1 min at 60°C, 1 min at 72°C) and a single final elonga-
tion step for 3 min at 72°C. Mean CT value was calculated
and LRRC8A/LRRC8D were normalized to ARP2/3.
LRRC8A mutants
The LRRC8A-GFP expression vector was generated previ-
ously (Sørensen et al. 2016b). The LRRC8A mutants were
made by homologous recombination. Yeast cells were
transformed with BamHI. SalI and HindIII (Fermentas,
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Thermo Fischer Scientific) digested pPAP7160 vector (Sør-
ensen et al. 2016b) and two LRRC8A cDNA fragments, an
upstream and a downstream cDNA fragment both contain-
ing the mutation sites. The cDNA fragments were obtained
through regular PCR using AccuPol polymerase (VWR,
Denmark), a human LRRC8A-EGFP cDNA ORF clone
(Sørensen et al. 2016b) and the following primers: LRRC8A
(forward): 50-ATA TAA GCA GAG CTG GTT TAG TGA
ACC GTC AGA TCG GGT TGA ACC ATG ATT CCG
GTG ACA GAG CT-30; LRRC8A (reverse): 50-ACC CCG
GTG AAC AGC TCC TCG CCC TTG CTC ACC ATG
GCC TGC TCC TTG TCA GC-30; LRRC8A(p.Tyr382Phe)
(forward): 5‘-TCA TTG ACC AAT TTG ACC CGC TC-3‘;
LRRC8A(p.Tyr382Phe) (reverse): 5‘-GAG CGG GTC AAA
TTG GTC AAT GA-3‘; LRRC8A(p.Tyr386Phe) (forward):
5‘-GAC CCG CTC TTT TCC AAG CGC-3‘; LRRC8A
(p.Tyr386Phe) (reverse): 5‘- GCG CTT GGA AAA GAG
CGG GTC -3‘; LRRC8A(p.Lys501Arg) (forward): 5‘-GCT
GCA CAT CAG GTT CAC CGA CA-3‘; LRRC8A
(p.Lys501Arg) (reverse): 5‘-TGT CGG TGA ACC TGA TGT
GCA GC-3‘ (TAG Copenhagen A/S, Denmark). The
3‘-LRRC8A PCR product carried a 35-nucleotide sequence
identical to the 50-coding sequence of EGFP on the
pPAP7160 vector, whereas the 50-LRRC8A PCR product
carried a 35-nucleotide sequence identical to the pPAP7160
vector upstream to the restriction enzyme digestion-site
(Sørensen et al. 2016b).
The yeast cells were grown for 2–3 days at 37°C on Leu-
Lys-agar plates added 0.5% V-200 and 8 ng/mL tetracy-
cline. Following incubation, 2–3 colonies were collected
and transferred to Leu-Lys media. Leu-Lys media con-
tained 10% ASD-10, 2% glucose, 0.01% CaCl2, 1% leucine,
and 1% lysine in ddH2O (autoclaved before use) and
added 0.5% V-200 and 8 ng/mL tetracycline. The yeast
cells were grown for additional 2 days on a shaker at 37°C.
Uracil-positive cells were used to select for the presence of
a rejoined plasmids obtained by homologous end-joining
with the two cDNA fragments. Hereafter, the transformed
yeast cells were lysed by centrifugation (3000 g, 5 min),
addition of 1:1 lyticase buffer (100 mmol L1 Tris-HCl,
pH 8.0, 100 mmol L1 EDTA and 2/3 LB) and 10 lL lyti-
case (5 unit/lL in TE buffer, Sigma). The yeast cells were
incubated 1 h at 37°C and shaken thoroughly. Afterwards,
the cells were transferred to 10 lL 20% SDS, mixed, and
frozen (80°C). The LRRC8A-expression vector was puri-
fied using a NucleoSpin Plasmid DNA purification kit
(MACHEREY NAGEL). DNA yield was amplified by
E. coli transformation (OmniMax cells), followed by
NucleoBond Xtra Midi Plasmid DNA Purification
(MACHEREY NAGEL). The correct nucleotide sequences
were confirmed by DNA sequencing (Eurofins Genomics,
Germany). The plasmid concentrations were measured on
NanoDrop (Thermo Fischer Scientific).
Plasmid transfection of HEK-293 lrrc8a/
cells
HEK-293 lrrc8a/ cells grown to 70% confluence in six-
well plates were transfected with empty vector
(pPAP7160), LRRC8A-EGFP, or one of the three mutants
(LRRC8A-p.Tyr382Phe-EGFP, LRRC8A-p.Tyr386Phe-EG-
FP or LRRC8A-p.Lys501Arg-EGFP). The cells were trans-
fected with 2500 ng plasmid/well (total volume = 2 mL
DMEM/well) using LipofectamineTM 2000 Transfection
Reagent (5 lL per transfection). Briefly, LipofectamineTM
and the individual plasmids were each mixed with 100 lL
DMEM transfection media (i.e., without penicillin/strepto-
mycin and FBS) and incubated for 5 min at RT. During
incubation, the cell culture media covering the cells was
replaced by 1.6 mL DMEM transfection media. Following
incubation, the transfection reagent and the plasmid solu-
tions were mixed together and left for another 30 min at
room temperature. Finally, the transfection mixture was
dripped over the cells and the cells were added 200 lL
FBS/well. The cells were incubated 24 h before initiation
of the experiment in the cell culture incubator. For the
taurine release experiments, the cell culture media was
changes to transfection-reagent-free DMEM media con-
taining FBS before loading the cells with [3H]taurine.
Cell surface biotinylation and membrane
protein isolation
Cells, grown to 80% confluence in four T75 flasks (each),
were biotinylated and labeled proteins isolated according
to the manufactures instructions in the Pierce Cell Surface
Protein Isolation Kit (Thermo Fisher Scientific). SDS-
PAGE and western blotting were used to analyze the
expression of LRRC8A and Na+/K+-ATPase (positive
plasma membrane control / loading control) in both
whole cell lysate and purified samples.
Statistics
All data are statistically tested (SigmaPlot version 12) by
one-way ANOVA with Fisher LSD Method as posttest or
by Student0s t-test. In bar- and scatter-plots the error bars
signify standard error of the mean (SEM).
Results
Effect of hypotonic adaptation on LRRC8A
expression and volume-sensitive taurine
release
Figure 1A shows, in congruence with previously published
data (Holm et al. 2013), that release of taurine from A549
2018 | Vol. 6 | Iss. 19 | e13869
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is transiently increased in response to hypotonic exposure.
Cells, grown in standard DMEM medium, were subjected
to a 28% decrease in osmolarity (321 231 mOsm),
whereas cells adapted for 24 h to hypotonic growth med-
ium (220–226 mOsm for 24 h) were subjected to a 30%
decrease in osmolarity (231161 mOsm). In both cases,
cells obtained a maximal fractional rate constant for taurine
release within 6 min following hypotonic exposure, that is,
0.06 min1 and 0.23 min1 for control cells and hypotoni-
cally adapted cells, respectively. Inactivation of the volume-
sensitive taurine release pathway is almost complete after
24 h exposure to the 231 mOsm medium, that is, the rate
constant for cells adapted to 231 mOsm medium was
0.0015  0.00006 min1 (n = 3) compared to 0.0010 
0.00004 min1 (n = 8) for control cells in isotonic
321 mOsm. To investigate the difference in the maximal
fractional rate constants, following a quantitatively similar
osmotic challenge, that is, 28–30% reduction in tonicity,
we tested how control cells and hypotonically adapted cells
responded to increasingly larger osmotic challenges. From
Figure 1B it is seen that the maximal rate constants for the
swelling-induced taurine release for cells, incubated in
321 mOsm medium, is significantly activated after a 25%
reduction in osmolarity (321?245 mOsm; fractional rate
constant = 0.035 min1). However, the hypotonically
adapted A549 cells revealed a significant activation after
13% decrease in tonicity (231?201 mOsm; fractional rate
constant = 0.015 min1). Furthermore, after the “set-
point,” that is, the cell volume required for activation of
the VRAC complex, has been reached, the relationship
between medium osmolarity and the maximal rate constant
for the swelling-induced taurine release, in control cells and
hypotonically adapted cells, increases in what appears to be
a sharp escalation (Fig. 1B). Similar correlation between
activation of volume-sensitive taurine efflux and anisotonic
solutions has previously been demonstrated for bovine
articulate chondrocytes (Hall and Bush 2001). The differ-
ence in maximal fractional rate constants observed for
A549 cells (Fig. 1A) thus reflects that the shift in hypotoni-
cally adapted cells from 231 mOsm to 161 mOsm ends in
the steeper part of the curve, whereas shift from 321 mOsm
to 231 mOsm in control cells barely reaches the steep part
of the escalation curve (Fig. 1B). From Figure 1C it is seen
that although hypotonic adaptation reduces LRRC8A
mRNA accumulation by approximately 40%, the LRRC8A
protein expression is concomitantly increased 1.6 fold.
Hence, higher LRRC8A protein expression following hypo-
tonic adaptation does not reflect an increase LRRC8A gene
transcription. Whether, the reduced LRRC8A mRNA accu-
mulation reflects a putative negative feedback from an
increased LRRC8A protein expression was not investigated.
To test whether an increased LRRC8A expression could
affect the set-point for the volume-sensitive taurine
release in A549 cells we exposed cisplatin-sensitive
(A549WT) and cisplatin-resistant A549 (A549RES) cells to
hypotonic challenges in the range 279–200 mOsm. The
A549RES cells were included, because we have previously
shown that although total LRRC8A protein expression is
significantly increased in the A549RES cells the VRAC
complex activity is low due to a reduced LRRC8A availabil-
ity in the plasma membrane (Sørensen et al. 2016b). Fig-
ure 1D shows, in congruence with our previous data
(Sørensen et al. 2016b), that the swelling-induced taurine
release is reduced in A549RES cells compared to the
A549WT cells following exposure to hypotonic media
(321 mOsm?279..200 mOsm). To align the osmosensitiv-
ity in the two cell lines we multiplied the maximal rate
constant for the swelling-induced taurine release in
A549RES cells by the ratio between maximal rate constants
for A549WT and A549RES after exposure to 200 mOsm
(Lambert 2003). From Figure 1D we see that the trans-
formed values for taurine release in A549RES and A549WT
cells are identical within the osmolarity range tested (com-
pare open and gray bars). Hence, a reduced LRRC8A avail-
ability in the plasma membrane, as seen in A549RES, does
not shift the set-point for activation of the VRAC complex.
To test whether prevention or boosting of taurine loss
during a hypotonic exposure would affect taurine loss dur-
ing a subsequent hypotonic exposure we exposed cells to
the CysLT1 receptor antagonist zafirlukast or to H2O2. In
agreement with earlier observations in A549 cells (Holm
et al. 2013), acute exposure to the zafirlukast, elicits a 95%
reduction in the swelling-induced taurine release in control
and hypotonically adapted cells (Fig. 1E). However, zafir-
lukast mediated prevention of taurine loss during the first
hypotonic challenge, has no effect on the subsequent sec-
ondary swelling-induced taurine release performed after
zafirlukast washout (Fig. 1E). It has previously been shown
that the ROS production increases following hypotonic
exposure and that ROS boost volume-sensitive taurine
release (Lambert 2003; Friis et al. 2008; Lambert et al.
2009; Holm et al. 2013). However, Figure 1E shows that
whereas acute exposure to H2O2 potentiates the swelling-
induced taurine release 2.71 fold in control cells exposed to
hypotonic medium (321?231 mOsm), this effect is
reduced in hypotonically preexposed cells (231?
161 mOsm) and even reversed into an inhibition in cells
preexposed for 24 h in hypotonic medium containing
H2O2. This could indicate that ROS, generated under the
first hypotonic stress, limit osmolyte loss under a subse-
quent hypotonic challenge and that the effect depends on
the ROS concentration. From Figure 1E it is also seen that
the effect of H2O2 preexposure on swelling-induced taurine
release is mimicked by the tyrosine phosphatase inhibitor
vanadate. Cysteines are sensitive to oxidation and as they
are found in the active site of protein tyrosine phosphatases
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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(PTP) it is assumed that the effect of ROS partly reflects
oxidative inhibition of PTP and consequently enhancement
of the effect of opposing protein tyrosine kinases (Lambert
et al. 2015b). In this context it is noted that volume-sensi-
tive taurine release in A549 has been shown to be inhibited
by the general tyrosine kinase inhibitor Genistein and the
selective Janus kinase (JAK) inhibitor cucurbitacin (Holm
et al. 2013). Whether, down-regulation of the ROS sensi-
tivity of the volume-sensitive taurine release following
adaptation to hypotonic conditions and/or chronic ROS
exposure reflects reduced tyrosine kinase expression/activ-
ity was not investigated further.
Effect of oxidative stress (H2O2) on LRRC8A
subunit expression, VRAC activity, and
apoptotic cell signaling
In accordance with the data in Figure 1 the time traces in
Figure 2A show that following hypotonic exposure (321?
200 mOsm) the swelling-induced taurine release is boosted
by H2O2, added acutely, but inhibited when H2O2 is pre-
sent for 24 h prior to the subsequent hypotonic challenge
(maximal rate constants: Control 0.20  0.007 min1;
Acute ROS exposure 0.23  0.02 min1; ROS preexposure
0.15  0.02 min1). However, Figure 2B illustrates an
inverse correlation between LRRC8A protein expression
and the volume-sensitive taurine release following preex-
posure to H2O2, that is, protein expression is increased 1.3
and 1.5 fold following 6 and 24 h of exposure to H2O2,
respectively, whereas the maximal fractional release con-
stant is concomitantly reduced by 8% and 24% compared
to control cells. Furthermore, ROS preexposure also
reduces the relative inactivation of the taurine release path-
way (Fig. 2B), that is, 20 min posthypotonic exposure the
inactivation was 62  2%, 59  5% and 49  6% for
control and H2O2 preexposed for 6 h or 24 h cells, respec-
tively (100% inactivation would have indicated that the
rate constant had reached the isotonic value). It is noted
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that a reduced inactivation, that is, an increased open
probability of the VRAC complex could compensate for a
reduced maximal activity in relation to net loss of osmo-
lytes. However, at the end of the release experiment (time
30 min) the control cells and cells preexposed to H2O2
contained 10  1% (n = 7) and 17  5% (n = 4) of their
original pool of [3H]taurine, respectively, that is, pro-
longed exposure to H2O2 reduces volume-sensitive net loss
of taurine in A549 cells. Hence, although H2O2 preexpo-
sure increases LRRC8A protein expression this does not
govern a higher volume-sensitive taurine release in A549
cells. From Figure 2C it is seen that the mRNA accumula-
tion for LRRC8A and LRRC8D, which together constitutes
the volume-sensitive taurine release pathway, is unaffected
by 24 h incubation with H2O2. These data indicate that
upregulation in LRRC8A protein expression, following cell
stress (hypotonic or H2O2 exposure), does not imply shift
in the LRRC8A gene transcription.
Cell stress is known to instigate apoptosis and/or cell
cycle arrest. From Figure 2D it is seen that H2O2 expo-
sure causes a 4.1, 2.3, and 5.0 fold increase in the expres-
sion of phosphorylated p53 (transcription factor
indicating activation of proapoptotic transcription),
NOXA (Bcl-2 family member indicating progression of
apoptosis) and p21 (cyclin-dependent kinase inhibitor
p21 indicating cell growth inhibition), respectively. This
indicates that an increase in LRRC8A expression, follow-
ing prolonged H2O2 exposure, correlates with instigation
of apoptosis and inhibition of cell cycle progression. The
Forkhead box proteins FoxO1, FoxO3 and FoxO4 are
ubiquitously expressed transcription factors that similar
to p53 act as tumor suppressors though promotion of cell
cycle arrest and instigation of apoptosis (Morris et al.
2015). FoxOs are negatively regulated through PI3K-Akt
signaling, that is, FoxO3 mediated transcription is pre-
vented by Akt mediated phosphorylation (T32, S243,
S315) and nuclear export. However, FoxO3 phosphoryla-
tion by the AMP-dependent kinase AMPK (S413) does
not shift its localization and instead leads to an increased
transcriptional activity (Greer et al. 2007). From
Figure 2E (western blot insertion) it is seen that the
expression of FoxO3 is dramatically increased within
hours following H2O2 exposure, which is taken to indi-
cate that the H2O2 induced increase in LRRC8A expres-
sion, correlates progression of apoptosis through p53 and
presumably FoxO3 mediated activity. However, although
Figure 1. Swelling induced release of taurine and LRRC8A mRNA/protein expression in A549 cells following repetitive hypoosmotic exposure or
exposure to varying degrees of hypoosmotic challenge. Taurine release, mRNA accumulation and protein expression, were measured by tracer
technique, qRT-PCR and SDS-PAGE/western blotting, respectively. (A) Fractional rate constants (min1) for [3H]taurine release from cisplatin-
sensitive A549 (A549WT) cells, preloaded with [3H]taurine, were determined under isotonic/hypotonic conditions and plotted versus time. One
group of cells, preincubated in isotonic growth medium, was exposed for 10 min to isotonic Ringer (321 mOsm) before exposure to hypotonic
Ringer (321//231 mOsm) (○, n = 10). Another group, adapted for 24 h in hypotonic growth medium (220–226 mOsm), was exposed for 10
min to hypotonic Ringer with a similar tonicity (231 mOsm) followed by an additional hypotonic challenge (231//161 mOsm Ringer) (●, n = 9).
Shift in tonicity is indicated by the arrow. Data represent mean values  SEM. *indicates statistical increased compared to the prehypotonic
values (P < 0.05, ANOVA, Fisher LSD Method). (B) Set-point for volume-sensitive taurine release in A549WT cells, preexposed to isotonic
medium (○, n = 4) or hypotonic medium (●, n = 3), before exposure to Ringers within the range 329–161 mOsm (○) or 250–161 mOsm (●),
respectively. Fractional rate constants for taurine release were at each tonicity followed as function of time, as indicated in A, and the maximal
fractional rate constant determined as the rate constant 6 min following shift in tonicity. *indicates statistically increased compared to the rate
constant before hypotonic challenge, that is, 0.0010  0.00004 min1 (○, 321 mOsm) and 0.0015  0.00006 min1 (●, 231 mOsm)
(P < 0.05, ANOVA, Fisher LSD Method). (C) LRRC8A mRNA accumulation and protein expression were determined in A549WT cells grown in
isotonic growth medium (control, open bars) or adapted for 24 h to hypotonic growth medium (220–226 mOsm, black bars). Insert:
Representative western blots for LRRC8A and actin (Lane 1: Control cells; Lanes 2: Hypotonically adapted cells). Values for hypotonic adapted
cells are given relative to control cells and represent means  SEM of 4 (mRNA) and 6 (protein) sets of independent experiments. *indicates
statistical different compared to control cells (P < 0.05, paired Student0s t-Test). (D) Volume set point for activation of the volume-sensitive
taurine release was determined in A549WT (open bars) and cisplatin-resistant A549 cells (A549RES) (black bars) as the maximal rate constant
obtained 6 min after exposure to hypotonic media in the range 279–200 mOsm. Maximal rate constant are given as mean values  SEM from
3 sets of independent experiments. The aligned values (gray bars) for A549RES were obtained by multiplication of A549RES values with the
ratio between the maximal rate constant for A549WT and A549RES after exposure to hypotonic medium (200 mOsm). *indicates statistical
increased compared to rate constants obtained under isotonic conditions (P < 0.05, ANOVA, Fisher LSD Method). (E) Effect of H2O2, vanadate
and zafirlukast preexposure on the maximal fractional rate constant for taurine release following hypoosmotic challenge. Rate constants for
swelling-induced release of [3H]taurine were plotted as function of time (see Panel A) for A549WT cells preexposed to 321 mOsm medium
before hypoosmotic challenge in 231 mOsm (open bars) or cells adapted to 231 mOsm for 24 h (black and gray bars) before hypoosmotic
challenge in 161 mOsm, respectively. Maximal rate constants, obtained 6 min after hypoosmotic exposure, were determined in the absence
(control, open bars), following acute exposure (black bars) or 24 h pre-exposure (gray bars) to H2O2 (100 lmol L
1), vanadate (50 lmol L1) or
Zafirlukast (60 lmol L1). Maximal fractional rate constants, are given relative to the maximal constant for the respective control cells, that is,
0.067  0.006 min1 (321//231 mOsm; n = 10) and 0.234  0.012 min1 (231//161 mOsm; n = 10). *indicates statistical different compared
to control values (P < 0.05, ANOVA, Fisher LSD Method).
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Figure 2. Effect of exogenous H2O2 on LRRC8A mRNA accumulation, LRRC8A protein expression, swelling induced taurine release, and
intracellular signaling associated with apoptosis and cell growth. Taurine release, mRNA accumulation and protein expression in A549WT were
measured by tracer technique, qRT-PCR and SDS-PAGE/western blotting, respectively. (A) Fractional rate constant (min1) for [3H]taurine release
was determined in A549WT cells under isotonic conditions (321 mOsm) and following reduction in the osmolarity to 200 mOsm (shift in
tonicity indicated by the arrow) in the absence (control, open circles) or presence of 100 lmol L1 H2O2 (acute exposure, closed squares).
Alternatively, cells were preexposed to isotonic growth medium containing 100 lmol L1 H2O2 for 24 h prior to the release experiment (closed
circles). Rate constants at each time point represent mean values from 7 (Control), 4 (preexposed) and 4 (acute exposure) sets of experiments.
*indicates that maximal rate constant, obtained 6 min after hypotonic exposure, was significantly different from control cells (P < 0.05, paired
Student0s t-Test). (B) A547WT cells were preexposed to isotonic growth medium containing 100 lmol L1 H2O2 for 6 or 24 h prior to taurine
release experiments for determination of maximal rate constants (min1), inactivation of the VRAC complex activity and LRRC8A protein
expression. Values  SEM for maximal rate constant, inactivation of taurine release pathway (4 sets with 6 and 24 h exposure) and protein
expression (4/10 sets for 6/24 h exposure, respectively) are given relative to control cells not exposed to H2O2. Insert: Representative western
blots for LRRC8A and GAPDH (Lane 1: Control cells; Lanes 2 and 3: Cells exposed to 25 lmol L1 H2O2 for 6 and 24 h, respectively; Lanes 4
and 5: Cells exposed to 100 lmol L1 H2O2 for 6 and 24 h, respectively). *indicates that values were significantly different from the control
cells (P < 0.05, paired Student0s t-Test). (C) LRRC8A and LRRC8D mRNA accumulation was determined in control A549WT cells and cells
exposed for 24 h to 100 lmol L1 H2O2. Values, calculated relative to untreated control cells, are given as means  SEM of 4 sets of
experiments. (D) A549WT cells were incubated in growth medium containing 100 lmol L1 H2O2 for 24 h before proteins were extracted and
tested for expression of phosphorylated p53 (P-p53), NOXA, p21, and GAPDH (house holding protein). Protein expression was normalized to
GAPDH (9, 5, and 8 sets for P-p53, NOXA and p21, respectively), and presented as means  SEM of values relative to non-treated control
cells. Insert: Representative western blots for P-p53, p21, NOXA and GAPDH for (Lane 1: Control cells; Lanes 2 and 3: Cells exposed to
25 lmol L1 H2O2 for 6 and 24 h, respectively; Lanes 4 and 5: Cells exposed to 100 lmol L
1 H2O2 for 6 and 24 h, respectively). *indicates
that the protein expression of apoptotic markers was significantly different from control cells (P < 0.05, paired Student0s t-Test). (E) A549WT
cells were incubated in growth medium containing 100 lmol L1 H2O2 for 24 h. Proteins were extracted at the time points indicated and
tested for expression of total and phosphorylated Akt / FoxO3A. Protein expression ratios between phosphorylated and total proteins were
calculated in 4 sets of experiments and data presented as mean values  SEM of the ratios relative to control cells. Insert: Representative
western blots for FosO3A, Akt, P-FosO3A, and P-Akt (Lane 1: Control cells; Lanes 2 to 6: Cells exposed to 100 lmol L1 H2O2 for ½, 1, 3, 6,
and 24 h, respectively). *indicates that the protein expression was significantly different from control cells (P < 0.05, paired Student0s t-Test).
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phosphorylation of FoxO3 on S413 initially is significantly
increased by H2O2 it diminishes with time concomitantly
to the increase in Akt activity, indicated as the ratio
between the expression of phosphorylated Akt and total
Akt (Fig. 2E).
Effect of cisplatin exposure on LRRC8A
subunit expression, VRAC activity, and
growth-associated signaling
Activation of the serine/threonine kinase Akt, which is
normally associated with cell growth, has in several stud-
ies been associated with modulation of volume-sensitive
taurine release (Lambert et al. 2015b) as well as develop-
ment of cisplatin resistance (Gagnon et al. 2004; Wino-
grad-Katz and Levitzki 2006; Hahne et al. 2012). In
human breast (MDA MB-468) carcinoma cells, it has
been shown that cisplatin activates Akt in a way that
depends on the epidermal growth factor receptor (EGFR)
and Src kinase (Winograd-Katz and Levitzki 2006). More-
over, in human lung A549 cancer cells Akt-1 amplifica-
tion was found to promote cisplatin resistance through
the mTORC1/p70S6K-1 signaling pathway (Liu et al.
2007). We have investigated the effect of cisplatin and
oxaliplatin on the activation of Akt, measured as its Ser-
473 phosphorylation. Figure 3A, representative western
blot (insert) and quantification, shows that cisplatin and
oxaliplatin induce a transient activation of Akt within
24 h where maximal activity is obtained following 6 h
treatment. The Akt activation is inhibited by co-treatment
with the PI3K inhibitor Wortmannin, indicating that the
cisplatin-induced Akt activation depends on the PI3
kinase (Fig. 3B). Moreover, whereas the PTEN inhibitor
HOpic and the mTORC1 inhibitor rapamycin slightly
potentiate phosphorylation of Akt in the absence of cis-
platin (Fig. 3B), they have no significant effect on the
cisplatin-induced Akt activation (Fig. 3B). However, co-
treatment with the anti-oxidant BHT significantly reduces
the cisplatin-induced Akt activity, indicating that activa-
tion of cisplatin induced Akt activation involves ROS
(Fig. 3B).
Short-term exposure to cisplatin has previously been
demonstrated to increase LRRC8A protein in human
ovarian carcinoma (A2780) cells significantly (Sørensen
et al. 2014). From the data presented in Figure 3C–F it is
seen that although 6–24 h pretreatment with cisplatin
increases the expression of LRRC8A protein, it reduces
the swelling-induced taurine release and delays channel
inactivation. Figures 3E and F also show that inhibition
of PI3K activity by addition of wortmannin not only lim-
its the swelling-induced taurine release and delays inacti-
vation of the VRAC complex but also eradicates the effect
of cisplatin on the swelling-induced taurine release. As
mTORC1 operates downstream to Akt and mTORC2
mediates the growth-factor-induced phosphorylation of
Akt on Ser-473 we tested the effect of mTORC1 inhibi-
tion (rapamycin) and mTORC2 inactivation (Rictor
siRNA silencing). In congruence with data obtained from
mouse fibroblasts (Lambert et al. 2014) rapamycin treat-
ment boosts the swelling-induced taurine release and
accelerates inactivation of the release pathway (Figs. 4A–
C). Furthermore, the data in Figs 4B and C indicate that
the inhibitory effect of cisplatin on the volume-sensitive
taurine release seen in Figures 3E and F is overruled by
rapamycin. mTORC2 is, in contrast to mTORC1, insensi-
tive to rapamycin inhibition (Bai et al. 2017) and it is
assumed that the contribution of mTOR at a low-dose of
rapamycin allocates from an effect via mTORC1 to an
effect via mTORC2. From Figures 4E and F it is seen that
inhibition of mTORC2, through Rictor silencing (verified
in Fig. 4D), decreases the swelling-induced taurine release
and inactivation of the release pathway. This is similar to
the effect of PI3K inhibition (Wortmannin, Figs. 3E and
F) and opposite to mTORC1 inhibition (rapamycin,
Figs. 4A–C). Based on this, it is suggested that rapamycin
induced inhibition of mTORC1, potentiates Akt activa-
tion through mTORC2. Hence, the effect of cisplatin on
VRAC is partly mediated through modulation of the
PI3K/PTEN-mTORC2-Akt pathway and intracellular ROS
production.
Correlation between LRRC8A protein
overexpression and p53 phosphorylation in
response to cell stress
The data in Figures 2B and D show that there is a corre-
lation between LRRC8A expression and activation of p53
following exposure to H2O2. This prompted us to test
whether other forms of cell stress could elicit a similar
response. From Figure 5A it is seen that LRRC8A expres-
sion as well as p53 phosphorylation are increased follow-
ing preexposure to pharmacological 5-LO inhibitors
(ETH), CysLT1 receptor-antagonists (zafirlukast), phos-
phatase inhibitors (HOpic, Vanadate) as well as hypoos-
motic conditions. This indicates that prolonged drug
exposure and osmotic perturbation trigger a general cell
stress condition resulting in increased LRRC8A protein
expression and p53 activation and hence instigation of
apoptosis. To determine whether p53 phosphorylation is
dictated by increased LRRC8A or whether p53 controls
the LRRC8A expression we exposed A549 cells to the cell-
permeable proteasome inhibitor MG132. It has previously
been shown that p53 expression in NIH3T3 mouse
fibroblasts increased dramatically after addition MG132,
which was taken to indicate that p53 levels in unpertu-
bated cells was kept low by proteasomal degradation
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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(Lambert et al. 2015a). From Figure 5B it is seen that 6hs
exposure to MG132 increases p53 phosphorylation signifi-
cantly but has no effect on LRRC8A expression in the cis-
platin sensitive A549WT cells. Furthermore, LRRC8A
expression is significantly reduced in MG132-treated
A549RES even though p53 activity is high (Fig. 5B).
Thus, increased p53 activity does not seem to elicit an
increase LRRC8A expression. The increased p21 expres-
sion following MG132 exposure probably reflects the con-
comitant increase in p53 activation. To test the effect of
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Figure 3. Effect of cisplatin on Akt phosphorylation, swelling-induced taurine release, and VRAC inactivation. Protein expression was
determined by SDS-PAGE/western blotting (WB) followed by protein quantification using UN-SCAN-IT. Rate constants and inactivation for the
volume-sensitive taurine release were obtained by tracer technique. (A) Transient Akt activation in A549 cells following exposure to cisplatin
and oxaliplatin. Cells were exposed to 20 lmol L1 cisplatin or oxaliplatin. Lysates were taken and tested for P-Akt and total Akt expression at
the time points indicated. P-Akt/Akt expression ratios from 3 sets of experiments were in each setup calculated relative to the untreated
controls and presented as mean values  SEM. Insert: Representative P-akt and total Akt western blots (Lane 1: Control cells; Lanes 2–6: 0.5 ,
1, 3, 6, 24 h exposure to cisplatin; Lanes 7–11: 0.5, 1, 3, 6, 24 h exposure to 20 lmol L1 oxaliplatin). * and # denote that P-Akt / Akt
expression ratios are statistically different from the ratio in untreated control or the maximal P-Akt/Akt ratio (time 6 h), respectively (one-way
ANOVA with Fischer’s LSD test. (B) A549 cells were exposed for 6 h to Wortmannin (Wort, 5 lmol L1), HOpic (5 lmol L1), Rapamycin (Rapa,
400 nmol/L) or BHT (0.5 mmol L1) in the absence or presence of 20 lmol L1 cisplatin. Lysates were taken and proceeded for detection of
total-Akt and P-Akt. Values indicate P-Akt/Akt expression ratios from 4 sets of experiments were in each setup calculated relative to the
untreated controls and presented as mean values  SEM. * and # denote statistically different from cells not treated with cisplatin and cells
treated with cisplatin, respectively (P < 0.05, one-way ANOVA with Fischer’s LSD test). (C, E, F) A549 cells were exposed to 20 lmol L1
cisplatin for 6 h before protein extraction/western blotting or initiation taurine release experiment. Fractional rate constant (min1) for taurine
release was determined from release of [3H]taurine and plotted versus time under isotonic and hypotonic conditions (C, shift in tonicity
indicated by the arrows). Maximal hypotonic taurine release (E) were obtained from the time traces and set relative to control cells not exposed
to cisplatin. The VSOAC inactivation (F) was calculated as indicated in Materials and Methods. The data represent mean values from five sets of
experiments  SEM. *Statistically different from untreated control (Student t-test). (D) LRRC8A protein expression was determined in control
and cells exposed for 6 h to cisplatin. Values are given relative to untreated control cells and represent mean  SEM of 3 sets of experiments.
*Statistically different from untreated control (P < 0.05, Student t-test).
2018 | Vol. 6 | Iss. 19 | e13869
Page 12
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
LRRC8A Protein Expression and VRAC Complex Activity M. D. Bach et al.
proteasome inhibition of the swelling-induced taurine
release we exposed A549 cells to hypotonic NaCl or KCl
media. The KCl medium was chosen in order to prevent
net loss of KCl and to prolong the time period where
VRAC is maximally active (verified in Fig. 5C). From Fig-
ures 5C and D it is seen that MG132 increases the vol-
ume-sensitive taurine release in A549WT and A549RES
cells exposed to hypotonic NaCl and KCl media although
the LRRC8A protein expression is concomitantly unal-
tered (A549WT) or reduced (A549RES) (Fig. 5B). The
boosting effect on taurine release of proteasome inhibi-
tion is seen also in the presence of H2O2 (Fig. 5D).
Hence, proteasome inhibition does not seem to imply
regulation of the ROS sensitive elements involved in
modulation of VRAC complex activity. The LRRC8A pro-
tein itself is prone to oxidation and ubiquitination and
hence degradation via the proteasome due to the expres-
sion of tyrosine and lysine residues, respectively. Using
LRRC8A/ HEK cells in which we reinstalled vectors
coding for native LRRC8A, LRRC8A mutants with
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Figure 4. Role of mTORC1 and mTORC2 in regulation of swelling-induced taurine release. Cells were pretreated with cisplatin in the absence
or presence of rapamycin or siRNA. (A) Time course for taurine release under isotonic and hypotonic conditions in control cells or cells
preexposed to rapamycin (400 nmol L1, 6 h). Values are mean of 3–6 sets of experiments. (B and C) Maximal hypotonic taurine release (B)
and inactivation of the release pathway (C) were obtained as indicated in the legend to Figure 3 from the time traces in Panel A and presented
as mean values of 3–6 sets of experiments  SEM. *Statistically different from untreated control cells (P < 0.05, Students t-test). (D–F) A549
cells were transfected with scramble or Rictor siRNA for 48 h. (D) Rictor expression relative to histone (H3, house holding protein) expression
was determined from four sets of paired experiments and presented as mean values  SEM. Insert: Representative Richtor and H3 western
blots. *Statistically different from untreated control (Student t-test). (E) Fractional rate constant (min1) for taurine release versus time under
isotonic and hypotonic conditions (shift in tonicity is indicated by the arrow) in scramble (open circles) and Rictor (closed circles) siRNA
transfected A549 cells (one representative experiment is shown). (F) Maximal hypotonic taurine release constants were obtained from the time
traces and set relative to the scramble siRNA transfected controls. Data in C represent mean of 3 (scramble siRNA) and 6 (Rictor siRNA) sets of
experiments  SEM. *Statistically different from control (P < 0.05, Student t-test).
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tyrosine substituted with phenylalanine or lysine substi-
tuted with arginine we followed taurine release as a func-
tion of time under isotonic conditions (320 mOsm) and
following hypotonic exposure (200 mOsm). The maximal
rate constant (min1) for the volume-sensitive taurine
release was determined at 0.014  0.003 (native HEK,
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Figure 5. Correlation between LRRC8A expression, VRAC activity and p53 phosphorylation. (A) A549WT cells were incubated for 24 h in
isotonic growth medium containing 10 lmol L1 ETH (5-lipoxygenase inhibitor), 60 lmol L1 Zafirlukast (Zafir, CysLT1 receptor antagonist),
5 lmol L1 HOpic (PTEN inhibitor), 50 lmol L1 Vanadate (Van, phosphatase inhibitor), or hypotonic (Hypo) growth medium. Proteins were
extracted and tested for the expression of LRRC8A, phosphorylated p53 (P-p53) and GAPDH (house holding protein). Protein expression relative
to GAPDH was calculated and the increase in protein expression relative to control cells determined. Data shown represent mean values  SEM
from 6 (LRRC8A) and 4 (P-p53) sets of paired experiments. *indicates that the protein expression in drug-treated cells was significantly
increased from control cells (P < 0.05, paired Student0s t-Test). (B) A549WT (open bars) and A549RES (black bars) were preincubated for 6 h in
growth medium in the absence or presence of the proteasome inhibitor MG132. Proteins were extracted and tested for expression of LRRC8A,
phosphorylated p53 (P-p53), p21, and GAPDH. Protein expression was in 4 sets of experiments for each cell line normalized to GAPDH and
presented relative to the respective nontreated control cells. *indicates that the protein expression was significantly different from control cells
(P < 0.05, paired Student0s t-Test). (C) Fractional rate constants (min1) for [3H]taurine release from A549WT cells in isotonic/hypotonic NaCl or
KCl media. In KCl media Na+ was substituted by K+ to prevent net loss of KCl (RVD) and hence indirect inactivation of the volume-sensitive
taurine release pathway. Time traces represent 5 sets of independent experiments. (D) A549WT (open bars) and A549RES (black bars) cells
were preincubated for 6 h in growth medium in the absence (Control) or presence of MG132 (10 lmol L1), H2O2 (100 lmol L
1) or MG132
plus H2O2 before exposure to isotonic / hypotonic NaCl or KCl media. The fractional rate constants (min
1) for [3H]-taurine release was
followed with time under isotonic and hypotonic conditions and the maximal rate constant determined as the rate constant at time 6 min after
hypotonic exposure as indicated in C. Maximal rate constants are normalized to untreated control cells and presented as the mean
values  SEM. from 4 to 5 sets of experiments. * and # indicate statistical difference between H2O2/MG132 treated and control cells and
between H2O2 and H2O2/MG132-treated cells, respectively, (P < 0.05, ANOVA, Fisher LSD Method).
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n = 3), 0.006  0.001 (n = 6, LRRC8A/ HEK),
0.018  0.004 (KO with native LRRC8A, n = 6),
0.015  0.002 (KO with LRRC8A: Y?F382, n = 6),
0.017  0.004 (KO with LRRC8A: Y?F386, n = 6) and
0.012  0.001 (KO with LRRC8A: K?R382, n = 6).
Although, the taurine release was significantly reduced
(P = 0.05) following lysine to arginine substitution we
also found that the LRRC8A (K?R382) protein expres-
sion was significantly reduced to 57  10% (n = 3,
P = 0.03) of the protein expression in KO expressing the
native LRRC8A protein. Hence, the sites Y382/Y386 and
K501 in LRRC8A do not seem to play a role in posttrans-
lational modulation of LRRC8A and VRAC complex
activity.
Correlation between LRRC8A protein
expression in the plasma membrane and
VRAC activity
We have previously demonstrated that reduced VRAC
activity in A549 cells with acquired cisplatin resistance
correlated with a reduced LRRC8A expression in the
plasma membrane even though total LRRC8A protein
expression was unaffected or even increased (Sørensen
et al. 2016b). From Figure 6 it is seen that long-term
exposure to hypotonic conditions, which increases total
LRRC8A expression (Fig. 1C), is accompanied by
increased LRRC8A expression in the plasma membrane.
On the other hand, the expression of LRRC8A in the
plasma membrane is unaffected by long-term exposure to
H2O2 and cisplatin (Fig. 6) although total levels of
LRRC8A protein is increased (Figs 2B and 3D). Hence,
reduced VRAC activity following prolonged exposure to
hypotonic conditions, ROS and cisplatin, is likely not due
to the absence or reduced expression of the indispensable
LRRC8A subunit in the VRAC complex.
Discussion
Stress-induced modulation of LRRC8A
subunit expression and VRAC complex
activity
How cells perceive their volume and how a change in vol-
ume is transduced into a volume-regulatory response has
envisioned mechanical deformation/stretch of the plasma
membrane and changes in the cytoskeleton or dilution/
shift in the intracellular ionic strength through cell swel-
ling/shrinkage and subsequently activation of cell signal-
ing components (phospholipases, lipoxygenases, kinases,
phosphatases) involved in the instigation and execution
of the volume regulatory process (Pedersen et al. 1999,
2006; Lambert et al. 2006; Hoffmann et al. 2009). An
arising question is whether the VRAC complex itself is
equipped with a volume sensing capacity. Being the essen-
tial component of the VRAC complex a reduction in total
LRRC8A protein expression, following exposure to pro-
tolichesterinic acid (Thorsteinsdottir et al. 2016), gene
silencing (Qiu et al. 2014; Voss et al. 2014) or as a phe-
notypic characteristic in, for example, cisplatin-resistant
A2780 cells (Sørensen et al. 2014), correlate with a
reduced volume-sensitive taurine release. Likewise, a
reduction in LRRC8A protein availability in the plasma
membrane, as seen in A549RES compared to A549WT
cells (Sørensen et al. 2016b), results in reduced VRAC
complex activity, but an unaltered volume set-point for
activation. However, Syeda and coworkers recently
showed that LRRC8A (SWELL1), when co-expressed with
other LRRC8 subunits in an artificial bilayer system, was
activated by low ionic strength (Syeda et al. 2016).
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Figure 6. LRRC8A expression in the plasma membrane of A549
cells. Cells were exposed to isotonic conditions (Control), hypotonic
conditions and isotonic conditions in the presence of 100 lmol L1
H2O2 or 10 lmol L
1 cisplatin for 18hs. Proteins with components
exposed to the extracellular compartment were biotinylated and
cells were lysed. Biotinylated LRRC8A and Na+/K+-ATPase were
extracted and separated/quantified by SDS-PAGE/western blotting.
As the molecular weight of LRRC8A and Na+/K+-ATPase are close
(94 kDa/110 kDa) western blots were run in parallel on separate
gels. (A) Representative blots. Total indicates total cell homogenates
prepared from cells not treated with biotin. (B) Protein ratio
LRRC8A/Na+/K+-ATPase from 3 sets of experiments. *indicates
significantly increase compared to isotonic control cells (Student0s
t-test).
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Furthermore, Grodagna and coworkers demonstrated,
using expression of fluorescently tagged LRRC8 subunits
in Xenopus oocytes, that a LRRC8A/8D channel complex
was inhibited by oxidation (Gradogna et al. 2017).
Although, we find that mutation of preserved tyrosines in
LRRC8A (Tyr382, Tyr386) does not reduce volume-sensi-
tive activation, one cannot exclude that the reduction in
volume-sensitive taurine release, following H2O2 exposure
during hypotonically adaptation, could partly imply oxi-
dation and inactivation of the LRRC8D component in the
VRAC complex. A surprising observation was that overex-
pression of LRRC8A in HEK293T and HeLa cells was not
accompanied by an in increase in ICl,Swell but rather a
decrease compared to wild-type levels (Qiu et al. 2014;
Voss et al. 2014). Likewise, we observe that an increased
total LRRC8A expression, following hypotonic adaptation
(A549) and exposure to ROS and cisplatin (A2780) (Sør-
ensen et al. 2014, 2016a) correlates with reduction in vol-
ume-sensitive taurine release. Our data indicate that
LRRC8A mRNA accumulation is reduced after hypotonic
adaptation, which probably reflects negative feedback
from prolonged hypotonic conditions and / or an
increased LRRC8A protein expression. It is noted that the
increased LRRC8A availability in the plasma membrane,
as seen in hypotonically adapted A549 cells, could explain
the concomitant stronger correlation between medium
osmolarity and maximal rate constant for volume sensi-
tive taurine release, that is, VRAC activity. Currently we
assume that modulation of osmolyte transport via the
VRAC complex is mainly controlled through (1) post-
translational modulation of LRRC8 subunits, (2) shift in
the stoichiometry between LRRC8A and other LRRC8
family members, (3) modulation of the number of func-
tional VRAC complexes in the plasma membrane, and (4)
shift in the activity of signaling cascades involved in mod-
ulation of VRAC complex activity.
ROS mediated modulation of VRAC activity
ROS production increases during physiological stress, for
example, cell swelling, muscle contraction sepsis, and
anoxia (Lipton 1999; Nethery et al. 1999; Lambert 2003,
2007; Ørtenblad et al. 2003; Varela et al. 2004; Diaz-Eli-
zondo et al. 2006; Friis et al. 2008; Holm et al. 2013). In
the case of A549 cells it has previously been demonstrated
that swelling-induced taurine release is potentiated follow-
ing acute exposure to ROS but inhibited in the presence
of the NADPH oxidase inhibitor DPI (diphenyleneiodo-
nium) as well as the antioxidant BHT (Holm et al. 2013).
As A549 increase their ROS production within the first
minutes following hypotonic exposure it is assumed that
ROS could have an autocrine effect and promote release
of organic osmolytes via the VRAC complex. The 5-LO
activity is controlled by ROS and as 5-LO, by pharmaco-
logical and substrate inhibition, has been shown to be
required for swelling-induced activation of taurine in a
variety of cell types (Hall 1995; Lambert and Falktoft
2001; Lambert et al. 2001; Lambert 2003; Ørtenblad et al.
2003; Holm et al. 2013; Sørensen et al. 2014) the 5-LO
could constitute a primary target for ROS. In the present
study, it is demonstrated that the boosting effect of acute
exposure to ROS on the swelling-induced taurine release
similar to the effect of the phosphatase inhibitor vanadate
is weakened in hypotonically adapted cells and even
reversed into an inhibition in cells exposed to excess
H2O2 during the hypotonic adaptation period. Protein
tyrosine phosphatases are inhibited by ROS via oxidation
of a cysteine in the catalytic site (Huyer et al. 1997; Meng
et al. 2002) and as our experiments indicate that LRRC8A
availability in the plasma membrane is unaffected by pre-
exposure to H2O2 in A549 cells it is assumed that the
prolonged ROS exposure reduces VRAC activity due to a
shift in the protein tyrosine phosphorylation status of the
VRAC complex and/or cellular components involved in
the activation of the VRAC complex. It has previously
been shown in NIH3T3 mouse fibroblasts that the boost-
ing effect of ROS and vanadate is impaired in the pres-
ence of the broad-spectrum tyrosine kinase inhibitor
Genistein (Lambert 2003) implying that the shift in the
phosphorylation status could reflect shift in the activity of
protein tyrosine kinases. A variety of protein tyrosine
kinases, for example, epidermal growth factor receptor,
insulin receptor, Src, and Lck, are known to be regulated
by redox in cells (Kamata and Hirata 1999) and it has
been shown that protein tyrosine phosphorylation occurs
concomitant to activation of ICl,Swell (Davis et al. 2001)
and taurine efflux (Ochoa de la Paz et al. 2002) in a pro-
cess that in some occasions involves the focal adhesion
kinase (FAK, p125FAK) (Tilly et al. 1996; Ochoa de la
Paz et al. 2002). Auto phosphorylation of FAK, elicited
by its binding to b1-integrin, facilitates formation of a
FAK – Src protein tyrosine kinase complex (Ben Mahdi
et al. 2000) and subsequently phosphorylation of FAK in
its catalytic and C-terminal domains (Salazar and Rozen-
gurt 1999; Ben Mahdi et al. 2000). An elevated phospho-
rylation at Tyr576/Tyr577 in the catalytic domain of FAK,
detected in vanadate treated cells overexpressing chicken
FAK, is previously demonstrated to be essential for an
increase in FAK kinase activity (Maa and Leu 1998). In
congruence H2O2 has been shown to induce a time-
dependent phosphorylation of FAK in bovine pulmonary
artery endothelial cells, which occurs primarily through
inhibition of protein tyrosine phosphatases, specific to
FAK (Vepa et al. 1999). In this context it is noted that
the volume-sensitive taurine release in NIH3T3 cells has
been shown to be reduced following inhibition of kinase
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activity coupled to the epidermal growth factor (EGF)
receptor and boosted by application of EGF (Lambert
2003), whereas the volume-sensitive taurine release in
A549 is inhibited by the tyrosine kinase inhibitor Genis-
tein and the selective Janus kinase (JAK) inhibitor cucur-
bitacin (Holm et al. 2013). Whether adaptation in A549
cells to excess ROS involves shift in the expression/activity
of specific protein tyrosine receptor kinases was not inves-
tigated in the present study.
LRRC8A protein expression and apoptosis
Our present data indicate that exposure to ROS (H2O2)
as well as cisplatin induces an increase in LRRC8A
expression, Akt activity, p53 phosphorylation and subse-
quently apoptosis and presumably inhibition of cell cycle
progression (increase in p21). Reduction in cell volume,
due to net loss of ions (KCl), organic osmolytes (taurine
and other nonessential amino acids) and cell water is a
hallmark of AVD and it has been demonstrated that cell
shrinkage per se instigates apoptosis through induction of
protein kinase p38 and p53 mediated signaling, stimula-
tion of death receptor (CD95) trafficking to the plasma
membrane or impairment of growth factor-receptor-
mediated signaling (Hoffmann et al. 2009). In recent
years it has turned out that cisplatin resistance in cancer
cells can reflect down-regulation in the activity of vol-
ume-sensitive channels for K+, Cl and taurine (Lee et al.
2007; Poulsen et al. 2010; Min et al. 2011; Hoffmann and
Lambert 2014; Sørensen et al. 2014), which seems to limit
or postpone apoptosis. It is noted that restriction of tau-
rine loss via the VRAC complex as seen in, for example,
cisplatin-resistant A2780 cells (Sørensen et al. 2014)
might be envisaged as a survival strategy, as taurine
besides being a quantitative important osmolyte, also has
been indicated to reduce progression of the apoptotic
process following cell stress, for example, drug exposure,
ischemia/hypoxia and glucose supplementation, through
prevention of (1) mitochondrial dysfunction (2) upregu-
lation of proapoptotic messengers (Bax, Fas), (3) p53
mediated activity, (4) ROS generation, (5) Ca2+ mobiliza-
tion, (6) apoptosome assembly, and caspase activity
(Lambert et al. 2015b). In the context of brain physiol-
ogy, it has to be emphasized that taurine activates inhibi-
tory glycine/c-aminobutyric acid receptors (Le-Corronc
et al. 2011) and that limitation of taurine release during
ischemia- / hypoxia-induced cell swelling might affect
neurotransmission. We have previously shown that (1)
LRRC8A expression, hence activation of the LRRC8A and
presumably osmolyte transport via a VRAC complex, is
essential for cisplatin-induced instigation of the proapop-
totic transcription factor p53 and its down-stream signal-
ing (caspase-9/-3 activation, expression of p21Waf1/Cip1,
MDM2), (2) down-regulation of LRRC8A-dependent
transport activity contributes to acquirement of cisplatin
resistance in ovarian and lung carcinoma cells, and (3)
that activation of the LRRC8A-dependent channels is
upstream to the cisplatin-induced AVD as apoptosis
induced by hypertonic cell shrinkage does not require the
presence of LRRC8A/VRAC (Sørensen et al. 2016b). Our
present findings indicate that prolonged treatment of
A549 cells with ROS or inhibitors/receptor antagonists,
that are normally used to verify a role of element in the
volume signaling cascade, actually increases LRRC8A pro-
tein expression and concomitantly phosphorylation/acti-
vation of p53. In the case of H2O2 the exposure is
followed by instigation of apoptosis, cell cycle arrest as
well as a reduction in volume-sensitive taurine release.
The latter could reflect an attempt to limit AVD and the
apoptotic process. As was the case with cisplatin-induced
apoptosis the upregulated p53 activity is downstream to
the concomitant upregulation of LRRC8A, as an increase
in p53 phosphorylation per se, provoked by the presence
of the proteasome inhibitor MG132, is not accompanied
by an increase in LRRC8A. We have previously demon-
strated that a low p53 expression in unperturbed NIH3T3
mouse fibroblasts reflects a balance between high synthe-
ses of p53 and an equally high proteasome breakdown of
p53 which is prevented by the addition of MG132 (Lam-
bert et al. 2015a). It is noted that inhibition of
proteasome activity provokes an amplification of the
swelling-induced taurine release and presumably apoptosis
and cell cycle arrest (increased p53 phosphorylation, p21
expression). The effect of proteasome inhibition does not
seem to imply ubiquitination and proteomic removal of
LRRC8A, as mutation of a putative ubiquitination site on
LRRC8A diminished LRRC8A expression and VRAC
complex activity to the same extent.
FoxO3a phosphorylation in A549 cells decreases during
prolonged H2O2 exposure concomitantly to an increase in
Akt activity, which could indicate that Akt mediates
nuclear export and inactivation of FoxO3. FoxO3 medi-
ates transcriptional regulation of the ubiquitin ligase
adaptor Keap1 (Kelch-like ECH-associated protein 1)
which targets the nuclear factor Nrf2 (Nuclear factor (ery-
throid-derived 2)-like 2) for ubiquitination and proteaso-
mal degradation. As Nrf2 is a proto-oncogene, that
protects cells against cell damage and apoptosis through
transcriptional regulation of detoxifying enzymes and
anti-apoptotic members (Bcl-2, Bcl-XL), it is assumed
that increased Akt activity, following cisplatin and ROS
exposure, results in an increased expression of Nrf2 and
its down-stream anti-apoptotic genes. Akt also activates
the murine double minute-2 (MDM2), which negatively
regulates p53 activity (Steelman et al. 2011). As p53 sup-
press the Nrf2 promoter activity by blocking Sp1 binding
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to the Nrf2 promoter an increased Akt activity will not
only limit p53 mediated activation of apoptosis and cell
cycle arrest but also limit p53 mediated inhibition of
Nrf2. Hence, Akt will induce cell survival.
Cell stress and Akt-mTORC1/-mTORC2
signaling
The serine/threonine kinase mTOR is a well-characterized
substrate of Akt and it is known that Akt-mediated acti-
vation of mTOR occurs through phosphorylation and
inactivation of tuberous sclerosis complex 2 (TSC2),
which normally inhibits mTOR (Hay 2005). mTOR con-
stitutes the catalytic unit of mTORC1, which is distin-
guished from mTORC2 by having Raptor as catalytic
regulator. In contrast to mTORC1, that acts down-stream
to Akt, mTORC2 seems to be involved in phosphoryla-
tion (Ser-473) and activation of Akt in response to stimu-
lation of receptor-tyrosine kinases (Dasari and
Tchounwou 2014). Binding of the translation initiation
factor 4E-BP1 and the kinase p70-S6 to Raptor is
required for mTORC1 mediated phosphorylation of 4E-
BP1 and facilitation of cap-dependent translation. Rapa-
mycin forms a complex with its cellular receptor FKBP12
that subsequently disrupts Raptor and mTOR interaction
and hence prevent mTORC1 activation. It has been
demonstrated in epidermal cells that a low-dose of rapa-
mycin potentiated the mTORC2 pathway, that is,
increased SIN-1 (Thr-86) and Akt (Ser-473) phosphoryla-
tion (Bai et al. 2017). mTORC2, that contains the cat-
alytic regulator Rictor, has opposing functions compared
to mTORC1 (Gonzalez and Rallis 2017) and it has turned
out that mTORC2-mediated phosphorylation and activa-
tion of Akt seem to be required for cell cycle progression
in cancer cells (Hietakangas and Cohen 2008). We have
previously shown that mTORC1 activity, detected as
phosphorylation of 4E-BP1, is transiently increased in
mouse fibroblasts following hypoosmotic exposure, that
is, mTOR activity is significantly increased and boosted
by PTEN inhibition within minutes following osmotic cell
swelling but reduced following prolonged (4 h/24 h)
hypotonic adaptation (Lambert et al. 2014). Using
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Figure 7. Activation and stress modulation of cell signaling pathways involved in release of taurine through the VRAC complex in human lung
epithelial cell line A549. Volume-sensitive release of taurine through VRAC, with a presumable LRRC8A/D stoichiometry, requires phospholipase
A2, 5-LO and CysLT1 activity. The VRAC activity is attenuated by the CysLT1 receptor antagonist Zafirlukast and the 5-lipoxygenase inhibitor
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and vanadate. Cell growth factor-dependent modulation of VRAC involves the PI3K-Akt-mTOR signaling cascade. BpV(HOpic) and Wortmannin
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rapamycin, to mimic the effect of reduced mTORC1
activity, during prolonged hypotonic conditions it was
shown that reduced mTORC1 activity in the mouse
fibroblasts correlated with a reduce catalase mRNA accu-
mulation (Lambert et al. 2014). As catalase inhibition,
similar to rapamycin inhibition, boosted the volume-sen-
sitive taurine release in the mouse fibroblasts it was sug-
gested that chronic hypotonic exposure and mTORC1
inhibition reduce the antioxidative defense (Lambert et al.
2014). Whether a reduced ability to remove ROS con-
tributes to the reduced ROS sensitivity during hypotonic
adaptation can at the moment only be speculative.
In human lung A549 cancer cells Akt-1 amplification
was found to promote cisplatin resistance through the
mTORC1/p70S6K-1 signaling pathway (Liu et al. 2007).
We find that albeit cisplatin increases Akt phosphoryla-
tion /activity as well as LRRC8A protein expression in
A549 it concomitantly reduces VRAC complex activity.
Inhibition of PI3K activity by addition of wortmannin
prevents Akt activation and at the same time eradicates
the effect of cisplatin on Akt phosphorylation and VRAC
activity, that is, the effect of cisplatin on VRAC involves
PI3K-Akt signaling. Inhibition of mTORC1 with rapamy-
cin increases Akt phosphorylation but prevents the cis-
platin-induced reduction in VRAC activity. In contrast,
inhibition of mTORC2 through Rictor silencing reduces
similar to PI3K inhibition swelling-induced VRAC activa-
tion. mTORC2 is insensitive to rapamycin inhibition (Bai
et al. 2017) and it is assumed that the contribution of
mTOR at a low-dose of rapamycin allocates from an
effect via mTORC1 to an effect via mTORC2, that is,
inhibition of mTORC1, potentiates mTORC2-mediated
Akt activation. Hence, the effect of cisplatin on VRAC is
partly mediated through modulation of the PI3K/PTEN-
mTORC2-Akt pathway and intracellular ROS production.
Figure 7 highlights elements in the intracellular signaling
provoked by cell swelling (PLA2-5LO-CysLT1) and modu-
lated by ROS (NADH-oxidases, protein tyrosine kinases
and phosphatases) or cell growth factors (PI3K-Akt-
mTOR). In the present work, we demonstrate that inhibi-
tion of mTORC1 with rapamycin, similar to acute H2O2
exposure, boosts swelling-induced taurine release from
A549 cells, whereas Rictor knockdown significantly
reduced the release to the same level as achieved by treat-
ment with the PI3K inhibitor wortmannin. Signaling by
mTORC2 seems to boost volume-sensitive taurine release
in A549 cells and our data are taken to indicate that inhibi-
tion of mTORC1 with rapamycin, favors mTOR complex 2
formation and hence taurine release. Our current hypothe-
sis is that although prolonged exposure to excess ROS and
cisplatin instigates apoptosis and cell cycle arrest in human
alveolar carcinoma cells (A549) a concomitant increase in
LRRC8A protein expression and Akt activation seems to
reduce VRAC complex activity which would limit loss of
osmolytes (AVD) and hence progression of apoptosis.
Since the discovery that LRRCA was essential for
VRAC complex activity it has turned out that LRRC8A is
critical for a variety of physiological function, for exam-
ple, T-cell development (Kumar et al. 2014), cell prolifer-
ation (Rubino et al. 2018) and adipogenesis (Zhang et al.
2017). In the latter case it was indicated that during adi-
pocyte hypertrophy the increase in cell volume will acti-
vate LRRC8A and potentiate intracellular insulin signaling
and hence boost GLUT4 translocation to the plasma mem-
brane, glucose uptake as well as lipogenesis (Zhang et al.
2017). Furthermore, Zhang and coworkers also demon-
strated that LRRC8A (SWELL1) knock out in adipocytes
reduced insulin-PI3K-pAKT2 stimulated GLUT4 transloca-
tion and that LRRC8A knock down in vivo was associated
with an impaired glucose tolerance as well as insulin resis-
tance (Zhang et al. 2017). Our findings indicate that cell-
stress, for example , prolonged exposure to various drugs,
ROS, and anisotonic conditions, reduces VRAC activity in
human alveolar carcinoma cells even though the expression
of the essential VRAC component LRRC8A is concomi-
tantly increased. During treatment of cancer cells with cis-
platin a reduced VRAC activity will limit accumulation of
the Pt-based drug and hence instigation of apoptotic cell
death.
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